{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:22:15Z","timestamp":1787239335124,"version":"build-2736575974"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.metabol.2017.03.006","type":"journal-article","created":{"date-parts":[[2017,3,9]],"date-time":"2017-03-09T15:45:45Z","timestamp":1489074345000},"page":"94-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Treatment with high dose salicylates improves cardiometabolic parameters: Meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"71","author":[{"given":"Estifanos","family":"Baye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negar","family":"Naderpoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Misso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Teede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa J.","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7356-4523","authenticated-orcid":false,"given":"Barbora","family":"de Courten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2017.03.006_bb0005","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1331\/JAPhA.2009.09077","article-title":"Type 2 diabetes: where we are today: an overview of disease burden, current treatments, and treatment strategies","volume":"49","author":"Campbell","year":"2009","journal-title":"J Am Pharm Assoc (2003)"},{"key":"10.1016\/j.metabol.2017.03.006_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.metabol.2010.09.010","article-title":"Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes","volume":"60","author":"Nyenwe","year":"2011","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2017.03.006_bb0015","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1345\/aph.1M483","article-title":"Potential role of salicylates in type 2 diabetes","volume":"44","author":"Rumore","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.metabol.2017.03.006_bb0020","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1126\/science.8052854","article-title":"Inhibition of NF-kappa B by sodium salicylate and aspirin","volume":"265","author":"Kopp","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.metabol.2017.03.006_bb0025","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/23948","article-title":"The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta","volume":"396","author":"Yin","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2017.03.006_bb0030","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s00125-012-2819-3","article-title":"A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance","volume":"56","author":"Goldfine","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2017.03.006_bb0035","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.108.804294","article-title":"Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight\/obese middle-aged and older humans","volume":"119","author":"Pierce","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2017.03.006_bb0040","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.amjmed.2012.12.013","article-title":"Aspirin in the treatment and prevention of cardiovascular disease: past and current perspectives and future directions","volume":"126","author":"Hennekens","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.metabol.2017.03.006_bb0045","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2337\/dc07-1338","article-title":"Salsalate improves glycemia and inflammatory parameters in obese young adults","volume":"31","author":"Fleischman","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2017.03.006_bb0050","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1752-8062.2008.00026.x","article-title":"Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes","volume":"1","author":"Goldfine","year":"2008","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.metabol.2017.03.006_bb0055","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1042\/CS20140030","article-title":"Prevention of age-related endothelial dysfunction by habitual aerobic exercise in healthy humans: possible role of nuclear factor kappaB","volume":"127","author":"Walker","year":"2014","journal-title":"Clin Sci"},{"key":"10.1016\/j.metabol.2017.03.006_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11596-013-1063-5","article-title":"A meta-analysis of salicylates for type 2 diabetes mellitus","volume":"33","author":"Fang","year":"2013","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"10.1016\/j.metabol.2017.03.006_bb0065","doi-asserted-by":"crossref","first-page":"790","DOI":"10.2337\/db11-0931","article-title":"Salicylate downregulates 11beta-HSD1 expression in adipose tissue in obese mice and in humans, mediating insulin sensitization","volume":"61","author":"Nixon","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2017.03.006_bb0070","series-title":"Evidence synthesis pogram template for critical appraisal of a randomsied controlled trial (adapated from critical appraisal templates (2010) Centre for Clinical Effectiveness, southern health, Melbourne, Australia)","author":"MCHRI","year":"2013"},{"key":"10.1016\/j.metabol.2017.03.006_bb0075","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/oby.20991","article-title":"Salsalate treatment improves glycemia without altering adipose tissue in nondiabetic obese hispanics","volume":"23","author":"Alderete","year":"2015","journal-title":"Obesity"},{"key":"10.1016\/j.metabol.2017.03.006_bb0080","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jacl.2015.06.009","article-title":"Salsalate-induced changes in lipid, lipoprotein, and apoprotein concentrations in overweight or obese, insulin-resistant, nondiabetic individuals","volume":"9","author":"Ariel","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.metabol.2017.03.006_bb0085","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/dc13-1527","article-title":"The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes","volume":"37","author":"Barzilay","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2017.03.006_bb0090","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF02047894","article-title":"Long-term administration of acetylsalicylic acid in impaired glucose tolerance in addition to the diet: effects and limits","volume":"18","author":"Caviezel","year":"1981","journal-title":"Acta Diabetol Lat"},{"key":"10.1016\/j.metabol.2017.03.006_bb0095","first-page":"1077","article-title":"Effects of indomethacin, sulindac, naproxen, aspirin, and paracetamol in treated hypertensive patients","volume":"6","author":"Chalmers","year":"1984","journal-title":"Clin Exp Hypertens A"},{"key":"10.1016\/j.metabol.2017.03.006_bb0100","doi-asserted-by":"crossref","first-page":"826","DOI":"10.4158\/EP12064.OR","article-title":"Reduction of insulin resistance and plasma glucose level by salsalate treatment in persons with prediabetes","volume":"18","author":"Faghihimani","year":"2012","journal-title":"Endocr Pract"},{"key":"10.1016\/j.metabol.2017.03.006_bb0105","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00592-011-0329-2","article-title":"Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes","volume":"50","author":"Faghihimani","year":"2013","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.metabol.2017.03.006_bb0110","first-page":"287","article-title":"The effect of salsalate on biochemical factors and endothelial dysfunction of prediabetic patients: a randomized clinical trial","volume":"19","author":"Fakhri","year":"2014","journal-title":"J Res Med Sci"},{"key":"10.1016\/j.metabol.2017.03.006_bb0115","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.2337\/dc13-0859","article-title":"Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD)","volume":"36","author":"Goldfine","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2017.03.006_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-159-1-201307020-00003","article-title":"Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.[summary for patients in Ann intern med. 2013 Jul 2;159(1):I-32; PMID: 23817718]","volume":"159","author":"Goldfine","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.metabol.2017.03.006_bb0125","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-152-6-201003160-00004","article-title":"The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.[summary for patients in Ann intern med. 2010 Mar 16;152(6):I-40; PMID: 20231550]","volume":"152","author":"Goldfine","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.metabol.2017.03.006_bb0130","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/003655902753679454","article-title":"A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy","volume":"36","author":"Khajehdehi","year":"2002","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.metabol.2017.03.006_bb0135","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1161\/01.CIR.0000017863.52347.6C","article-title":"Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin","volume":"105","author":"Kharbanda","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2017.03.006_bb0140","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.2337\/dc13-2977","article-title":"Effect of salsalate on insulin action, secretion, and clearance in nondiabetic, insulin-resistant individuals: a randomized, placebo-controlled study","volume":"37","author":"Kim","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2017.03.006_bb0145","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00125-008-1239-x","article-title":"The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study","volume":"52","author":"Koska","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2017.03.006_bb0150","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1445-5994.1982.tb03826.x","article-title":"Non-steroidal anti-inflammatory drugs and blood pressure","volume":"12","author":"Mills","year":"1982","journal-title":"Aust N Z J Med"},{"key":"10.1016\/j.metabol.2017.03.006_bb0155","doi-asserted-by":"crossref","first-page":"e000609","DOI":"10.1161\/JAHA.113.000609","article-title":"The effect of salsalate therapy on endothelial function in a broad range of subjects","volume":"3","author":"Nohria","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.metabol.2017.03.006_bb0160","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/dom.12450","article-title":"Salsalate has no effect on insulin secretion but decreases insulin clearance: a randomized, placebo-controlled trial in subjects without diabetes","volume":"17","author":"Penesova","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2017.03.006_bb0165","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/ijcp.12310","article-title":"Aspirin in type 2 diabetes, a randomised controlled study: effect of different doses on inflammation, oxidative stress, insulin resistance and endothelial function","volume":"68","author":"Raghavan","year":"2014","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.metabol.2017.03.006_bb0170","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ijcard.2015.04.029","article-title":"Arterial stiffening and systemic endothelial activation induced by smoking: the role of COX-1 and COX-2","volume":"189","author":"Vlachopoulos","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.metabol.2017.03.006_bb0175","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/BF01478209","article-title":"Does chronic aspirin treatment increase blood pressure in man?","volume":"59","author":"Walter","year":"1981","journal-title":"Klin Wochenschr"},{"key":"10.1016\/j.metabol.2017.03.006_bb0180","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1001\/jamacardio.2016.0605","article-title":"Effect of targeting inflammation with salsalate: the TINSAL-CVD randomized clinical trial on progression of coronary plaque in overweight and obese patients using statins","volume":"1","author":"Hauser","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.metabol.2017.03.006_bb0185","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.2337\/dc09-1727","article-title":"The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis","volume":"33","author":"Sherifali","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2017.03.006_bb0190","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/pds.3586","article-title":"The long-term efficacy and safety of DPP-IV inhibitors monotherapy and in combination with metformin in 18,980 patients with type-2 diabetes mellitus--a meta-analysis","volume":"23","author":"Liu","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.metabol.2017.03.006_bb0195","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1463-1326.2004.00317.x","article-title":"The effect of acarbose on insulin resistance in obese hypertensive subjects with normal glucose tolerance: a randomized controlled study","volume":"6","author":"Rachmani","year":"2004","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2017.03.006_bb0200","doi-asserted-by":"crossref","first-page":"e000090","DOI":"10.1136\/bmjdrc-2015-000090","volume":"3","author":"Lexis","year":"2015","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.metabol.2017.03.006_bb0205","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S2213-8587(13)70152-9","article-title":"Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial","volume":"2","author":"Preiss","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2017.03.006_bb0210","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1007\/s11606-013-2548-4","article-title":"Early response to preventive strategies in the diabetes prevention program","volume":"28","author":"Maruthur","year":"2013","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.metabol.2017.03.006_bb0215","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0140-6736(02)08905-5","article-title":"Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial","volume":"359","author":"Chiasson","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2017.03.006_bb0220","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","article-title":"Pioglitazone for diabetes prevention in impaired glucose tolerance","volume":"364","author":"DeFronzo","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2017.03.006_bb0225","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2017.03.006_bb0230","doi-asserted-by":"crossref","first-page":"149-57.e2","DOI":"10.1016\/j.amjmed.2007.09.016","article-title":"Meta-analysis: metformin treatment in persons at risk for diabetes mellitus","volume":"121","author":"Salpeter","year":"2008","journal-title":"Am J Med"},{"key":"10.1016\/j.metabol.2017.03.006_bb0235","doi-asserted-by":"crossref","first-page":"804","DOI":"10.7326\/M15-2113","article-title":"Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. preventive services task force","volume":"164","author":"Guirguis-Blake","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.metabol.2017.03.006_bb0240","series-title":"U.S. preventive services task force evidence syntheses, formerly systematic evidence reviews. Aspirin use in adults: cancer, all-cause mortality, and harms: a systematic evidence review for the US preventive services task force","author":"Whitlock","year":"2015"},{"key":"10.1016\/j.metabol.2017.03.006_bb0245","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/03009748109095292","article-title":"Schelstraete. Comparison of serum salicylate levels and gastro-intestinal blood loss between salsalate (Disalcid)and other forms of salicylates","volume":"10","author":"Mielants","year":"1981","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.metabol.2017.03.006_bb0250","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/07315724.2003.10719326","article-title":"Insulin clearance in obesity","volume":"22","author":"Valera Mora","year":"2003","journal-title":"J Am Coll Nutr"},{"key":"10.1016\/j.metabol.2017.03.006_bb0255","doi-asserted-by":"crossref","first-page":"1504-15.e3","DOI":"10.1053\/j.gastro.2012.02.050","article-title":"Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells","volume":"142","author":"Din","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.metabol.2017.03.006_bb0260","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.pharmthera.2010.11.002","article-title":"AMPK and vasculoprotection","volume":"131","author":"Ewart","year":"2011","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.metabol.2017.03.006_bb0265","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2004-0921","article-title":"Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance","volume":"146","author":"Khamzina","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2017.03.006_bb0270","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3109\/07853890.2013.770333","article-title":"Inhibition of the mTOR pathway: a possible protective role in coronary artery disease","volume":"45","author":"Tarantino","year":"2013","journal-title":"Ann Med"},{"key":"10.1016\/j.metabol.2017.03.006_bb0275","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1530\/JOE-12-0351","article-title":"mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells","volume":"216","author":"Le Bacquer","year":"2013","journal-title":"J Endocrinol"},{"key":"10.1016\/j.metabol.2017.03.006_bb0280","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1126\/science.1215327","article-title":"The ancient drug salicylate directly activates AMP-activated protein kinase","volume":"336","author":"Hawley","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.metabol.2017.03.006_bb0285","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1124\/mol.107.039479","article-title":"Salicylate blocks lipolytic actions of tumor necrosis factor-alpha in primary rat adipocytes","volume":"73","author":"Zu","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.metabol.2017.03.006_bb0290","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/BF03401534","article-title":"Adiponectin: regulation of its production and its role in human diseases","volume":"11","author":"Shehzad","year":"2012","journal-title":"Hormones"},{"key":"10.1016\/j.metabol.2017.03.006_bb0295","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/clpt.2009.88","article-title":"Utility of adiponectin as a biomarker predictive of glycemic efficacy is demonstrated by collaborative pooling of data from clinical trials conducted by multiple sponsors","volume":"86","author":"Wagner","year":"2009","journal-title":"Clin Pharmacol Ther"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049517300860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049517300860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:14:13Z","timestamp":1758428053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049517300860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":59,"alternative-id":["S0026049517300860"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2017.03.006","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment with high dose salicylates improves cardiometabolic parameters: Meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2017.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}